Table 2.

Sources of unpublished genotype frequency data

ProjectCountryCasesControlsPopulationSNPsIncludedReference
deCODEIceland1,619 cases identified from a list maintained by the Icelandic Cancer Registry that contains all 4,144 Icelandic prostate cancer patients diagnosed from January 1, 1955, to June 31, 2006.30,779 controls (43.3% male) from genetic research projects at deCODE: some diagnosed with common diseases (cardiovascular, endocrine, autoimmune, psychiatric, and neurologic); others randomly selected from the Icelandic genealogic database.Caucasian (100%)rs1801133Yes(30)
rs1805087
rs2236225
rs1051266
rs202676
CGEMS*United States1,188 cases diagnosed among men enrolled in the screening arm of the PLCO cancer screening trial who had no history of prostate, lung or colon cancer at randomization.1,110 controls selected by incidence-density sampling from the screening arm of the PLCO trial.Caucasian (100%)rs1801133Yes(31)
rs1805087
rs2236225
rs1051266
rs202676
FHS SHARe†United States172 cases identified at routine examinations or by health history updates among 5,209 Original and 5,124 Offspring Cohort participants in the FHS.231 unrelated (to each other and to cases) cancer-free controls randomly selected from among the same FHS cohorts.Caucasian (100%)rs1805087Yes(32)
rs1801394
rs2236225
rs202676
UKGPCSUnited Kingdom1,854 cases diagnosed in the United Kingdom through clinical symptoms, selected from the UK Genetic Prostate Cancer Study on the basis of age ≤60 y (64%) or first or second-degree family history of prostate cancer (36%).1,894 controls selected from among men invited to participate in the ProtecT study who had a PSA level of <0.5 ng/mL.Caucasian (100%)rs1801133Yes(33)
rs1805087
rs2236225
rs1051266
rs202676
ProtecT studyUnited Kingdom1,600 cases diagnosed during recruitment of men age 50-69 y to a UK population–based trial of treatments for localized prostate cancer. Men underwent a biopsy if they had a PSA level of ≥3 ng/mL.1,855 controls selected at random from among men age 50-69 y invited to participate in the ProtecT study who had a PSA level of <3 ng/mL or PSA of ≥3 ng/mL and a negative biopsy, plus 1,203 “low PSA” controls (PSA level, <0.5 ng/mL). Of the controls in these two groups, 344/1,855 and 622/1,203 were also used by the UKGPCS.Caucasian (>98%)rs1801133Yes—
rs1801131
rs1805087
rs1801394
rs2236225
rs1051266
rs202676
rs1979277

Abbreviations: CGEMS, Cancer Genetic Markers of Susceptibility; PLCO, Prostate, Lung, Colon, and Ovarian; FHS SHARe, Framingham Heart Study SNP Health Association Resource; UKGPCS, UK Genetic Prostate Cancer Study.